KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial.

J Michiel Zeeuw, Ruby Kemna, Mahsoem Ali, Sophie van Eck, Nina J Wesdorp, Joran Roor, Jan Hein T M van Waesberghe, Janneke E van den Bergh, Irene M G C Nota, Shira I Moos, Susan van Dieren, Martinus J van Amerongen, Marinde J G Bond, Thiery Chapelle, Ronald M van Dam, Marc R W Engelbrecht, Michael F Gerhards, Dirk J Grunhagen, Thomas M van Gulik, John J Hermans, Koert P de Jong, Joost M Klaase, Niels F M Kok, Wouter K G Leclercq, Mike S L Liem, Krijn P van Lienden, I Quintus Molenaar, Gijs A Patijn, Arjen M Rijken, Theo M Ruers, Cornelis Verhoef, Johannes H W de Wilt, Tineke E Buffart, Rutger-Jan Swijnenburg, Cornelis J A Punt, Inez M Verpalen, Jaap Stoker, Joost Huiskens, Geert Kazemier, CAIRO5 research group

Eur J Cancer 228 115738

PMID40912057
PMCID-
DOI10.1016/j.ejca.2025.115738
发表日期2025-09-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

INTRODUCTION: This study aimed to assess whether total tumor volume (TTV) outperforms RECIST1.1 for treatment response assessment in patients with colorectal liver metastases (CRLM), and to investigate TTV as a predictive biomarker for the optimal systemic treatment regimen for individual patients with initially unresectable CRLM. METHODS: Patients with initially unresectable liver-only CRLM from the phase 3 CAIRO5 trial (NCT02162563) were included. All patients received induction systemic treatment. Baseline TTV and changes in TTV and RECIST1.1 in response to systemic treatment were calculated using the CT scans before systemic treatment and at first follow-up, and were assessed for their prognostic and predictive value with multivariable Cox regression models. Results In total, 425 patients were included. In multivariable analyses, baseline TTV (adjusted HR [aHR] for 100 mL vs 10 mL, 2.44 [95 % CI, 1.25-4.76]; P = 0.006) and relative change in TTV were the strongest predictors for OS (aHR for 0 % change vs 50 % decrease, 2.57 [1.83-3.60]; P < 0.0001). In contrast, RECIST1.1 was not independently associated with OS (aHR for partial response vs progressive disease, 0.63 [95 % CI, 0.33-1.20]). Higher baseline TTV predicted a stronger treatment benefit of FOLFOX-/FOLFIRI-bevacizumab vs FOLFOX-/FOLFIRI-panitumumab on OS (Pinteraction=0.017). CONCLUSION: This study demonstrates that TTV (i) outperforms traditional risk factors for OS prognostication, and (ii) may be a more accurate and sensitive treatment response assessment method compared to the currently used RECIST1.1 system in patients with initially unresectable CRLM. Moreover, TTV assessment is a promising approach for individualized clinical decision-making between bevacizumab and panitumumab.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。